In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial ...

Belgium’s largest drugmaker UCB (Euronext: UCB) today revealed that it has received approval from Japan’s Pharmaceuticals and ...

Huge numbers of Brits could be driving without having notified the DVLA about their pre-existing conditions that should be ...

The FDA has approved Johnson & Johnson’s nipocalimab (Imaavy) for adults and paediatric patients 12 years of age and older with generalized myasthenia gravis (gMG) and anti-acetylcholine ...

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, announced ...

The venom of a scorpion is among the most expensive liquids on Earth, commanding an astronomical price of over $10 million ...

The desire for patients to have a personalized approach to care is repeated throughout the ad, which was produced by Avalere Health Chicago.

Learn more about whether BioCryst Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The FDA has approved Johnson & Johnson’s drug Imaavy for the treatment of generalized myasthenia gravis, a chronic autoimmune neuromuscular disorder. The approval covers adults and pediatric patients ...